title: Long term perturbation of endocrine parameters and cholesterol metabolism after discontinued abuse of anabolic androgenic steroids.
abstract: OBJECTIVE
  To study the long-term impact of anabolic androgenic steroid (AAS) abuse on the cholesterol profile, and the potential to suppress endocrine activity in men working out at gym facilities. To study the relation between urinary biomarkers for testosterone and nandrolone abuse and the UGT2B17 genotype and time profile.
  
  
  METHODS
  Subjects (N = 56) were recruited through Anti-Doping Hot-Line. Serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), plasma levels of low density lipoprotein (LDL), high density lipoprotein (HDL) and urinary steroid profile were regularly measured for a period of up to one year after cessation of intramuscular AAS abuse.
  
  
  CONCLUSIONS
  A sustained suppression of LH, and FSH was observed for several months. The nandrolone urinary biomarker 19-NA was detectable several months after the last nandrolone intake and was correlated to the levels of LH and FSH. Testosterone abuse on the other hand was detectable only for a few weeks, and some of the testosterone abusers did not test positive due to a genetic deletion polymorphism of the UGT2B17. Significantly increased levels of HDL and decreased levels of LDL were observed for 6-months after cessation of AAS abuse.
  
  
  CONCLUSIONS
  Some individuals had a sustained suppression of LH and FSH for a period of 1 year whereas the cholesterol profile was normalized within 6 month. The long term consequences of these findings remain to be established.
authors: Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital, SE-141 86 Stockholm, Sweden. nina.garevik@ki.se
authors: Nina
authors: N
authors: Gårevik
authors: Emmanuel
authors: E
authors: Strahm
authors: Mats
authors: M
authors: Garle
authors: Jonas
authors: J
authors: Lundmark
authors: Lars
authors: L
authors: Ståhle
authors: Lena
authors: L
authors: Ekström
authors: Anders
authors: A
authors: Rane
mesh_terms: D045930:Anabolic Agents / Q000008:administration & dosage*; D000728:Androgens / Q000008:administration & dosage*; D015415:Biomarkers / Q000378:metabolism; D002784:Cholesterol / Q000378:metabolism*; D005640:Follicle Stimulating Hormone / Q000097:blood; D014453:Glucuronosyltransferase / Q000235:genetics; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D015778:Minor Histocompatibility Antigens
chemical_list: D045930:Anabolic Agents; D000728:Androgens; D015415:Biomarkers; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D015778:Minor Histocompatibility Antigens; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002784:Cholesterol; D014453:Glucuronosyltransferase; C500513:UGT2B17 protein, human